Visceral Leishmaniasis Portfolio

By 2020, DNDi aims to deliver from its VL-specific portfolio:

  • Potentially a safe, effective, low-cost, and short-course oral combination treatment
  • A new treatment for PKDL that is shorter course and better tolerated than current options
  • Treatment options for HIV/VL co-infected patients
  • A new first-line treatment regimen for visceral leishmaniasis in Latin America

 

Cutaneous Leishmaniasis Portfolio

By 2020, DNDi aims to deliver from its CL-specific portfolio:

  • A safe, effective, and shorter-course treatment for cutaneous leishmaniasis

 

The current portfolio for both visceral and cutaneous leishmaniasis includes:

Research

Research

Aminopyrazoles
Booster H2L
CGH VL Series 1
Daiichi-Sankyo LH2L
DNDI-5421 & DNDI-5610 Oxaboroles
Leish H2L
Leish L205 Series
Translation

Translation

CpG-D35
DNDI-6148 Oxaborole
DNDI-0690 Nitromidazole
DNDI-5561
GSK3186899/DDD853651 – GSK3494245/DDD1305143
New CL Combination Therapies
Development

Development

MF/PM Combination for Africa
New treatments for HIV/VL
New treatments for PKDL
New VL treatments Latin America
Implementation

Implementation

SSG&PM
New VL Treatments – Asia

 

For more details on each project, see DNDi‘s Global Portfolio